Skip to main content
SpringerLink
Log in

Nephrotic syndrome developing during induction chemotherapy for childhood acute lymphoblastic leukemia

  • Case Report
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

This report is the first to document minimal change nephrotic syndrome occurring during induction chemotherapy for childhood acute lymphoblastic leukemia (ALL). This occurrence lends further support to the theory of immune cell dysregulation being central to the pathogenesis of nephrotic syndrome in ALL, rather than alternative postulations that this association is due to an increased risk of malignancy secondary to prior immunosuppressive treatment for nephrotic syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Papper S. Nephrotic syndrome and neoplasm. The findings to date, with practical implications. Postgrad Med. 1984;76(147–8):53–8.

    Google Scholar 

  2. Dabbs DJ, Striker LM, Mignon F, Striker G. Glomerular lesions in lymphomas and leukemias. Am J Med. 1986;80:63–70.

    Article  CAS  Google Scholar 

  3. Ronco PM. Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int. 1999;56:355–77.

    Article  CAS  Google Scholar 

  4. Sinha R, AlAbbas A, Dionne JM, Hurley RM. Simultaneous occurrence of atypical hemolytic uremic syndrome and acute lymphoblastic leukemia: a case report and literature review. Pediatr Nephrol. 2008;23:835–9.

    Article  Google Scholar 

  5. Lee JC, Yamauchi H, Hopper J Jr. The association of cancer and the nephrotic syndrome. Ann Intern Med. 1966;64:41–51.

    Article  CAS  Google Scholar 

  6. Da’as N, Polliack A, Cohen Y, Amir G, Darmon D, Kleinman Y, et al. Kidney involvement and renal manifestations in non-Hodgkin’s lymphoma and lymphocytic leukemia: a retrospective study in 700 patients. Eur J Haematol. 2001;67:158–64.

    Article  Google Scholar 

  7. Bhatia M, Kher K, Minniti CP. Acute lymphoblastic leukemia in a child with nephrotic syndrome. Pediatr Nephrol. 2004;19:1290–3.

    Article  Google Scholar 

  8. Kuis W, de Kraker J, Kuijten RH, Donckerwolcke RA, Voute PA. Acute lymphoblastic leukaemia after treatment of nephrotic syndrome with immunosuppressive drugs. Helv Paediatr Acta. 1976;31:91–5.

    CAS  PubMed  Google Scholar 

  9. Mackie FE, Roy LP, Stevens M. Onset of leukaemia after levamisole treatment for nephrotic syndrome. Pediatr Nephrol. 1994;8:527–8.

    Article  CAS  Google Scholar 

  10. Muller W, Brandis M. Acute leukemia after cytotoxic treatment for nonmalignant disease in childhood. Eur J Pediatr. 1981;136:105–8.

    Article  CAS  Google Scholar 

  11. Perard L, Thomas X, Jaumain H, Theuil G, Bret M, Coronel B, et al. T-cell lineage acute lymphoblastic leukemia with chromosome 5 abnormality in a patient with Crohn’s disease and lipoid nephrosis. Ann Hematol. 2000;79:222–5.

    Article  CAS  Google Scholar 

  12. Rajpoot D, Tejani A, Rao S, Miller S. Focal segmental glomerulosclerosis in a child with acute lymphoblastic leukemia. Child Nephrol Urol. 1990;10:231–3.

    CAS  PubMed  Google Scholar 

  13. Sathiapalan RK, Velez MC, McWhorter ME, Irwin K, Correa H, Baliga R, et al. Focal segmental glomerulosclerosis in children with acute lymphocytic leukemia: case reports and review of literature. J Pediatr Hematol Oncol. 1998;20:482–5.

    Article  CAS  Google Scholar 

  14. Fiser RT, Arnold WC, Charlton RK, Steele RW, Childress SH, Shirkey B. T-lymphocyte subsets in nephrotic syndrome. Kidney Int. 1991;40:913–6.

    Article  CAS  Google Scholar 

  15. Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet. 1974;2:556–60.

    Article  CAS  Google Scholar 

  16. Garin EH. Circulating mediators of proteinuria in idiopathic minimal lesion nephrotic syndrome. Pediatr Nephrol. 2000;14:872–8.

    Article  CAS  Google Scholar 

  17. Bakker WW, van Luijk WH. Do circulating factors play a role in the pathogenesis of minimal change nephrotic syndrome? Pediatr Nephrol. 1989;3:341–9.

    Article  CAS  Google Scholar 

  18. Gonzalez E, Neuhaus T, Kemper MJ, Girardin E. Proteomic analysis of mononuclear cells of patients with minimal-change nephrotic syndrome of childhood. Nephrol Dial Transplant. 2009;24:149–55.

    Article  CAS  Google Scholar 

  19. Sahali D, Pawlak A, Valanciute A, Grimbert P, Lang P, Remy P, et al. A novel approach to investigation of the pathogenesis of active minimal-change nephrotic syndrome using subtracted cDNA library screening. J Am Soc Nephrol. 2002;13:1238–47.

    CAS  PubMed  Google Scholar 

  20. Hultin LE, Hausner MA, Hultin PM, Giorgi JV. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry. 1993;14:196–204.

    Article  CAS  Google Scholar 

  21. Kolstad A, Holte H, Fossa A, Lauritzsen GF, Gaustad P, Torfoss D. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica. 2007;92:139–40.

    Article  CAS  Google Scholar 

  22. Motto DG, Williams JA, Boxer LA. Rituximab for refractory childhood autoimmune hemolytic anemia. Isr Med Assoc J. 2002;4:1006–8.

    CAS  PubMed  Google Scholar 

  23. Sahali D, Pawlak A, Le Gouvello S, Lang P, Valanciute A, Remy P, et al. Transcriptional and post-transcriptional alterations of IkappaBalpha in active minimal-change nephrotic syndrome. J Am Soc Nephrol. 2001;12:1648–58.

    CAS  PubMed  Google Scholar 

  24. Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin’s lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res. 2005;65:264–76.

    CAS  PubMed  Google Scholar 

  25. Aggarwal N, Batwara R, McCarthy ET, Sharma R, Sharma M, Savin VJ. Serum permeability activity in steroid-resistant minimal change nephrotic syndrome is abolished by treatment of Hodgkin disease. Am J Kidney Dis. 2007;50:826–9.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We sincerely thank Dr Alex Magil (Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver) for his help with the biopsy slides.

Conflict of interest

All the authors have declared no competing interest.

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Pediatrics, British Columbia Children’s Hospital, Level 4 Ambulatory Care Building, 4480 Oak Street, Vancouver, BC, V6H3V4, Canada

    Chanel Prestidge & Douglas G. Matsell

  2. Division of Pediatric Haematology/Oncology/BMT, Department of Pediatrics, BCCH, Vancouver, Canada

    Shahrad Rod Rassekh

Authors
  1. Chanel Prestidge
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shahrad Rod Rassekh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Douglas G. Matsell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chanel Prestidge.

About this article

Cite this article

Prestidge, C., Rassekh, S.R. & Matsell, D.G. Nephrotic syndrome developing during induction chemotherapy for childhood acute lymphoblastic leukemia. Clin Exp Nephrol 15, 410–413 (2011). https://doi.org/10.1007/s10157-010-0401-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-010-0401-1

Keywords

Search

Navigation